Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer
°áÇÙ¹×È£Èí±âÁúȯ 2011³â 71±Ç 1È£ p.15 ~ p.23
½ÅÈ«ÁØ(Shin Hong-Joon) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÅ¿Á(Kim Tae-Ok) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
°Çö¿í(Kang Hyun-Wook) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Áö¼ö¿µ(Chi Su-Young) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÝÈñÁ¤(Ban Hee-Jung) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è¼ö¿Á(Kim Soo-Ok) - ¼³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±Ç¿ë¼ö(Kwon Yong-Soo) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¿ÀÀÎÀç(Oh In-Jae) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è±Ô½Ä(Kim Kyu-Sik) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÀ¯ÀÏ(Kim Yu-Il) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀÓ¼ºÃ¶(Lim Sung-Chul) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è¿µÃ¶(Kim Young-Chul) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Background: Gefitinib and erlotinib are useful, molecular targeted agents in patients with non-small-cell lung cancer(NSCLC) who failed previous chemotherapy. We compared the efficacy and toxicity of two drugs in patients with squamous cell lung cancer, most of whom are male smokers.
Methods: We retrospectively reviewed the clinical information on patients with NSCLC who were treated with gefitinib or erlotinib treatment at Chonnam National University Hwasun Hospital between July 2002 and November 2009. The overall response rate (ORR), overall survival (OS) and progression-free survival (PFS) were compared between the two drugs.
Results: A total of 182 (100 gefitinib vs. 82 erlotinib) of 584 patients treated by targeted agents had squamous histology. Of the 182 patients, 167 (91.7%) were male and 159 (87.4%) were smokers. The ORR and disease control rate (DCR) were 4.9% and 40.6%, and there was no significant difference between gefitinib and erlotinib (ORR, 5.0% vs 4.8%; p=0.970; DCR, 40.0% vs 41.4%; p=0.439). The median OS in the gefitinib group was 12.1 months, and that in the erlotinib was 12.7 months (hazard ratio [HR], 1.282; 95% confidence interval [CI], 0.771¡2.134; p=0.339). The median PFS for the gefitinib group was 1.40 months, compared with 1.37 months for the erlotinib group (HR, 1.092; 95% CI, 0.809¡1.474; p=0.564). Skin rash ¡Ãgrade 3 was more common in erlotinib (12.2%) than gefitinib (1.0%, p=0.003) groups.
Conclusion: This retrospective study showed that the two drugs appear to have similar antitumor efficacy and
toxicity except for skin rash.
Å°¿öµå
Carcinoma, Squamous Cell, gefitinib, erlotinib, Treatment Outcome
KMID :
0383820110710010015
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
the two drugs appear to have similar antitumor efficacy and toxicity except for skin rash.( more common in erlotinib)